Recent Updates
Recently added Catalysts
INSM

Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: BRIDGEWATER, N.J. , Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3 rd

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
3.7%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
Brensocatib
Phase 3 · Non-Cystic Fibrosis Bronchiectasis

Full Press Release Details

BRIDGEWATER, N.J. , Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 8:00 a.m. ET .
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com . The webcast will be archived for a period of 30 days following the conclusion of the live event.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a growing footprint across Europe and in Japan . For more information, visit www.insmed.com .
Last updated: Nov 24, 2020